[1]
Daher, S.; Shulzhenko, N.; Morgun, A.; Mattar, R.; Rampin, G.F.; Camano, L.; DeLima, M.G. Associations between cytokine gene polymorphisms and recurrent pregnancy loss. J. Reprod. Immunol., 2003, 58(1), 69-77.
[2]
Girardi, G. Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clin. Rev. Allergy Immunol., 2010, 39(3), 160-165.
[3]
Clifford, K.; Rai, R.; Watson, H.; Regan, L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum. Reprod., 1994, 9(7), 1338-1332.
[4]
Isaksson, R.; Titinen, A. Present concept of unexplained infertility. Gynecol. Endocrinol., 2004, 18(5), 278-290.
[5]
Mastrolia, S.A.; Mazor, M.; Holcberg, G.; Leron, E.; Beharier, O.; Loverro, G.; Erez, O. The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications. Thromb. Haemost., 2015, 113(6), 1236-1246.
[6]
De Santis, M.; Cavaliere, A.F.; Straface, G.; Di Gianantonio, E.; Caruso, A. Inherited and acquired thrombophilia: Pregnancy outcome and treatment. Reprod. Toxicol., 2006, 22(2), 227-233.
[7]
Greer, I.A. Thrombophilia: implications for pregnancy outcome. Thromb. Res., 2003, 109(2-3), 73-81.
[8]
Coriu, L.; Ungureanu, R.; Talmaci, R.; Uscatescu, V.; Cirstoiu, M.; Coriu, D.; Copaciu, E. Hereditary thrombophilia and thrombotic events in pregnancy: single-center experience. J. Med. Life, 2014, 7(4), 567-571.
[9]
Bombell, S.; McGuire, W. Cytokine polymorphisms in women with recurrent pregnancy loss: Meta-analysis. Aust. N. Z. J. Obstet. Gynaecol., 2008, 48(2), 147-154.
[10]
Granot, I.; Gnainsky, Y.; Dekel, N. Endometrial inflammation and effect on implantation improvement and pregnancy outcome. Reproduction, 2012, 144(6), 661-668.
[11]
Christiansen, O.B.; Nielsen, H.S.; Kolte, A.M. Inflammation and miscarriage. Semin. Fetal Neonatal Med., 2006, 11(5), 302-308.
[12]
Zolti, M.; Ben-Rafael, Z.; Meirom, R.; Shemesh, M.; Bider, D.; Mashiach, S.; Apte, R.N. Cytokine involvement in oocytes and early embryos. Fertil. Steril., 1991, 56(2), 265-272.
[13]
Arslan, E.; Colakoglu, M.; Celik, C.; Gezginc, K.; Acar, A.; Capar, M.; Azoz, M.; Akyurek, C. Serum TNF-alpha, IL-6, lupus anticoagulant and anticardiolipin antibody in women with and without a past history of recurrent miscarriage. Arch. Gynecol. Obstet., 2004, 270(4), 227-229.
[14]
Lee, B.E.; Jeon, Y.J.; Shin, J.E.; Kim, J.H.; Choi, D.H.; Jung, Y.W.; Shim, S.H.; Lee, W.S.; Kim, N.K. Tumor necrosis factor-α gene polymorphisms in Korean patients with recurrent spontaneous abortion. Reprod. Sci., 2013, 20(4), 408-413.
[15]
Van der Pool, T.; Jansen, P.M.; Vanzee, K.J.; Welborn, B.M.; De Jong, I.; Moldawer, L.L. Tumor necrosis factor-alpha induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood, 1996, 88(3), 922-927.
[16]
Esmon, C.T. Inflammation and thrombosis. J. Thromb. Haemost., 2003, 1(7), 1343-1348.
[17]
Cheng, S.B.; Sharma, S. Interleukin-10: a pleiotropic regulator in pregnancy. Am. J. Reprod. Immunol., 2015, 73(6), 487-500.
[18]
Triplett, D.A.; Harris, E.N. Anthiphospholipid antibodies and reproduction. Am. J. Reprod. Immunol., 1989, 21(3-4), 123-131.
[19]
Sanson, B.J.; Friederich, P.W.; Simioni, P.; Zanardi, S.; Hilsman, M.V.; Girolami, A.; ten Cate, J.W.; Prins, M.H. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb. Haemost., 1996, 75(3), 387-388.
[20]
Rai, R.S.; Regan, L.; Chirolie, A.; Donald, J.G.; Conen, H. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance. Br. J. Obstet. Gynaecol., 1996, 103(8), 842-844.
[21]
Grandone, E.; Margaglione, M.; Colaizzo, D.; Cappucci, G.; Paladini, D.; Martinelli, P.; Montanaro, S.; Pavone, G.; Di Minno, G.; Factor, V. Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb. Haemost., 1997, 77(6), 1052-1054.
[22]
Martinelli, I.; Taioli, E.; Cetin, I.; Merinoni, A.; Gerosa, S.; Villa, M.V.; Bozzo, M.; Mannucci, P.M. Mutations in coagulation factors in women with unexplained late fetal loss. N. Engl. J. Med., 2000, 343(14), 1015-1018.
[23]
Preston, F.E.; Rosendaal, F.R.; Walker, I.D.; Brie, E.; Berntorp, E.; Conard, J.; Legnanic, C.; Scharrer, I. Increased fetal loss in women with heritable trombophilia. Lancet, 1996, 348(9032), 913-916.
[24]
Santoro, R.; Iannaccaro, P.; Sottilotta, G. Prothrombotic gene mutations in women with recurrent abortions and intrauterine fetal death. Minerva Ginecol., 2005, 57(4), 447-450.
[25]
Behjati, R.; Modarressi, M.H.; Jeddi-Tehrani, M.; Dokoohaki, P.; Ghasemi, J.; Zarnani, A.H.; Aarabi, M.; Memariani, T.; Ghaffari, M.; Akhondi, M.A. Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. Ann. Hematol., 2006, 85(4), 268-271.
[26]
Settin, A.; Alkasem, R.; Ali, E.; El Baz, R.; Mashaley, A.M.; Factor, V. Leiden and prothrombin gene mutations in Egyptian cases with unexplained recurrent pregnancy loss. Hematology, 2011, 16(1), 59-63.
[27]
Isaoglu, U.; Ulug, P.; Delibas, I.B.; Yilmaz, M.; Kumtepe, Y.; Dogan, H.; Tasdemir, S. The association between inherited thrombophilia and recurrent pregnancy loss in Turkish women. Clin. Exp. Obstet. Gynecol., 2014, 41(2), 177-181.
[28]
Gao, H.; Tao, F.B. Prothrombin G20210A mutation is associated with recurrent pregnancy loss: a systematic review and meta-analysis update. Thromb. Res., 2015, 135(2), 339-346.
[29]
D’Uva, M.; Di Micco, P.; Strina, I.; Ranieri, A.; Alviggi, C.; Mollo, A.; Fabozzi, F.; Cacciapuoti, L.; Di Frega, M.T.; Iannuzzo, M.; De Placido, G. Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy. Biologics, 2008, 2(4), 897-902.
[30]
Ghee, C.B.; Burrows, R.F. Prothrombin G20210A mutation is not associated with recurrent miscarriages. Aust. N. Z. J. Obstet. Gynaecol., 2002, 42(2), 167-169.
[31]
Parand, A.; Zolghadri, J.; Nezam, M.; Afrasiabi, A.; Haghpanah, S.; Karimi, M. Inherited thrombophilia and recurrent pregnancy loss. Iran. Red Crescent Med. J., 2013, 15(12)e13708
[32]
Goodman, C.S.; Coulam, C.B.; Jeyendran, R.S.; Acosta, V.A.; Roussev, R. Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss? Am. J. Reprod. Immunol., 2006, 56(4), 230-236.
[33]
Ren, A.; Wang, J. Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis. Fertil. Steril., 2006, 86(6), 1716-1722.
[34]
Yousefian, E.; Kardi, M.T.; Allahveisi, A. Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism in Iranian Women With Idiopathic Recurrent Pregnancy Losses. Iran. Red Crescent Med. J., 2014, 16(7)e16763
[35]
Wu, O.; Robertson, L.; Twaddle, S.; Lowe, G.D.; Clark, P.; Greaves, M.; Walker, I.D.; Langhorne, P.; Brenkel, I.; Regan, L.; Greer, I. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening(TREATS) study. Health Technol. Assess., 2006, 10(11), 1-110.
[36]
Ferroni, P.; La Farina, F.; Palmirotta, R.; Martini, F.; Raparelli, V.; Nigro, C.; Riondino, S.; Rampini, M.R.; Basili, S.; Guadagni, F. Predictive value of thrombopath determination in women with infertility and pregnancy complications. Chim. Clin. Acta, 2010, 411(1-2), 37-42.
[37]
Mathonnet, F.; de Mazancourt, P.; Denninger, M.H.; Morot, M.; Benattar, N.; Giudicelli, Y. Role of factor VIII on activated protein C resistance ratio in inflammatory diseases. Br. J. Haematol., 1996, 95(2), 423-425.
[38]
Miller, C.H.; De Staercke, C.; Benson, J.; Hooper, W.C.; Dilley, A.; Evatt, B.L.; Benito, C.; Patterson-Barnett, A.; Eller, D.; Philipp, C.S. Elevated factor VII as a risk factor for recurrent fetal loss. Relationship to factor VII gene polymorphism. Thromb. Haemost., 2005, 93(6), 1089-1094.
[39]
Riondino, S.; Ferroni, P.; La Farina, F.; Martini, F.; Palmirotta, R.; Guadagni, F.; Basili, S. Factor seven activating protease activity levels in women with recurrent pregnancy loss. Reprod. Sci., 2012, 19(3), 317-321.
[40]
Zhou, L.; Li, R.; Wang, R.; Huang, H.X.; Zhong, K. Local injury to the endometrium in controlled ovarian hyperstimulation cycles improves implantation rates. Fertil. Steril., 2008, 89(5), 1166-1176.
[41]
Tiboni, G.M.; Giampietro, F.; Gabriele, E.; Di Donato, V.; Impicciatore, G.G. Impact of a single endometrial injury on assisted reproductive technology outcome: a preliminary observational study. J. Reprod. Med., 2011, 56(11-12), 504-506.
[42]
Kalinka, J.; Radwan, M. The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion. Am. J. Reprod. Immunol., 2006, 55(2), 115-121.
[43]
Thum, M.; Abdalla, H.I.; Bhaskaran, S.; Harden, E.L.; Ford, B.; Sumar, N.; Shehata, H.; Bansal, A. The relationship of systemic TNF-alpha and INF-gamma with IVF treatment outcome and peripheral blood NK cells. Am. J. Reprod. Immunol., 2007, 57(3), 210-217.
[44]
Toder, V.; Fein, A.; Carp, H.; Torchinsky, A. TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J. Assist. Reprod. Genet., 2003, 20(2), 73-81.
[45]
Clark, D.A.; Ding, J.W.; Chaouat, G.; Coulam, C.B.; August, C.; Levy, G.A. The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and human. Am. J. Reprod. Immunol., 1999, 42(1), 37-43.
[46]
Gorczynsky, R.M.; Hadidi, S.; Yu, G.; Clark, D.A. The same immunoregolatory molecules contribute to successful pregnancy and transplantation. Am. J. Reprod. Immunol., 2002, 48(1), 18-26.
[47]
Thaxton, J.E.; Sharma, S. Interleukin-10: A Multi-Faceted Agent of Pregnancy. Am. J. Reprod. Immunol., 2010, 63(6), 482-491.
[48]
Brogin Moreli, J.; Cirino Ruocco, A.M.; Vernini, J.M.; Rudge, M.V.; Calderon, I.M. Interleukin 10 and Tumor Necrosis Factor-Alpha in Pregnancy: Aspects of Interest in Clinical Obstetrics. ISRN Obstet. Gynecol., 2012, 2012230742
[49]
Kwak-kim, J.Y.; Chung-Bang, H.S.; Ng, S.C.; Ntrivalas, E.I.; Mangubat, C.P.; Beaman, K.D.; Beer, A.E.; Gilman-Sachs, A. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum. Reprod., 2003, 18(4), 767-773.
[50]
Bohiltea, L.C.; Radoi, E.V. Interleukin-6 and interleukin-10 gene polymorphisms and recurrent pregnancy loss in Romanian population. Iran. J. Reprod. Med., 2014, 12(9), 617-622.
[51]
Babbage, S.J.; Arkwright, P.D.; Vince, G.S.; Perrey, C.; Pravica, V.; Quenby, S.; Bates, M.; Hutchinson, I.V. Cytokine promoter gene polymorphisms and idiopathic recurrent pregnancy loss. J. Reprod. Immunol., 2001, 51(1), 21-27.
[52]
Kamali-Sarvestani, E.; Zolghadri, J.; Gharesi-Fard, B.; Sarvari, J. Cytokine gene polymorphisms and susceptibility to recurrent pregnancy loss in Iranian women. J. Reprod. Immunol., 2005, 65(2), 171-178.
[53]
Palmirotta, R.; La Farina, F.; Ferroni, P.; Ludovici, G.; Nigro, C.; Savonarola, A.; Raparelli, V.; Riondino, S.; Rampini, M.R.; Guadagni, F.; Basili, S. TNFA gene promoter polymorphisms and susceptibility to recurrent pregnancy loss in Italian women. Reprod. Sci., 2010, 17(7), 659-666.
[54]
Vialard, F.; El Sirkasi, M.; Tronchon, V.; Boudjenah, R.; Molina-Gomes, D.; Bergere, M.; Mauduit, C.; Wainer, R.; Selva, J.; Benahmed, M. Tumor necrosis factor-308 polymorphism increases the embryo implantation rate in women undergoing in vitro fertilization. Hum. Reprod., 2013, 28(10), 2774-2783.
[55]
Bahadori, M.; Zarei, S.; Zarnani, A.H.; Zarei, O.; Idali, F.; Hadavi, R.; Jeddi-Tehrani, M. IL-6, IL-10 and IL-17 gene polymorphisms in Iranian women with recurrent miscarriage. Iran. J. Immunol., 2014, 11(2), 97-104.
[56]
Reid, J.G.; Simpson, N.A.; Walker, R.G.; Economidou, O.; Shillito, J.; Gooi, H.C.; Duffy, S.R.; Walker, J.J. The carriage of pro-infiammatory cytokine gene polymorphisms in recurrent pregnancy loss. Am. J. Reprod. Immunol., 2001, 45(1), 35-40.
[57]
Hill, J.A.; Choi, B.C. Maternal immunological aspects of pregnancy success and failure. J. Reprod. Fertil. Suppl., 2000, 55(1), 91-97.
[58]
Prigoshin, N.; Tambutti, M.; Larriba, J.; Gozorza, S.; Testa, R. Cytokine gene polymorphism in recurrent loss of unknown cause. Am. J. Reprod. Immunol., 2004, 52(1), 36-41.
[59]
Han, A.R.; Ahn, H.; Vu, P.; Park, J.C.; Gilman-Sachs, A.; Beaman, K.; Kwak-Kim, J. Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. Am. J. Reprod. Immunol., 2012, 68(5), 418-427.
[60]
Pinheiro, M.B.; Gomes, K.B.; Ronda, C.R.; Guimarães, G.G.; Freitas, L.G.; Teixeira-Carvalho, A.; Martins-Filho, O.A.; Dusse, L.M. Severe preeclampsia: association of genes polymorphisms and maternal cytokines production in Brazilian population. Cytokine, 2015, 71(2), 232-237.
[61]
Mustafa, R.; Ahmed, S.; Gupta, A.; Venuto, R.C. A comprehensive review of hypertension in pregnancy. J. Pregnancy, 2012, 2012, 1-19.
[62]
Kalkunte, S.; Lai, Z.; Norris, W.E.; Pietras, L.A.; Tewari, N.; Boij, R.; Neubeck, S.; Markert, U.R.; Sharma, S. Novel approaches for mechanistic understanding and predicting preeclampsia. J. Reprod. Immunol., 2009, 83(1-2), 134-138.
[63]
Vural, P.; Degirmencioglu, S.; Saral, N.Y.; Demirkan, A.; Akgul, C.; Yildirim, G.; Issever, H.; Eroglu, H. Tumor necrosis factor alpha, interleukin-6 and interleukin-10 polymorphisms in preeclampsia. J. Obstet. Gynaecol. Res., 2010, 36(1), 64-71.
[64]
De Groot, C.J.; Jansen, M.W.; Bertina, R.M.; Schonkeren, J.J.; Helmerhost, F.M.; Huizinga, T.W. Interleukin 10 -2849AA genotype protects against pre-eclampsia. Genes Immun., 2004, 5(4), 313-314.
[66]
James, A.H.; Jamison, M.G.; Brancazio, L.R.; Myers, E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol., 2006, 194(5), 1311-1315.
[67]
Greer, I.A. Clinical Practice. Pregnancy Complicated by Venous Thrombosis. N. Engl. J. Med., 2015, 373(6), 540-547.
[68]
Bates, S.M.; Greer, I.A.; Middeldorp, S.; Veenstra, D.L.; Prabulos, A.M.; Vandvik, P.O. American College of Chest Physicians. VTE,
thrombophilia, antithrombotic therapy, and pregnancy:
Antithrombotic Therapy and Prevention of Thrombosis. 9th ed:
American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. Chest,, 2012, 141(2), e691S-736S.
[69]
Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the
Puerperium. Green-top Guideline No. 37a, April 2015.
[70]
Bauersachs, R.M. Treatment of venous thromboembolism during pregnancy. Thromb. Res., 2009, 123(2), S45-S50.
[71]
Greer, I.A.; Nelson-Piercy, C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106(2), 401-407.
[72]
Bain, E.; Wilson, A.; Tooher, R.; Gates, S.; Davis, L.J.; Middleton, P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst. Rev., 2014, 2CD001689
[73]
Lindqvist, P.G.; Bremme, K.; Hellgren, M. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet. Gynecol. Scand., 2011, 90(6), 648-653.
[74]
Romualdi, E.; Dentali, F.; Rancan, E.; Squizzato, A.; Steidl, L.; Middeldorp, S.; Ageno, W. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J. Thromb. Haemost., 2013, 11(4), 270-281.
[75]
Pettila, V.; Kaaja, R.; Leinonen, P.; Ekblad, U.; Kataja, M.
Ikkala, E. Thromboprophylaxis with low molecular weight heparin(dalteparin) in pregnancy. Thromb. Res., 1999, 96(4), 275-282.
[76]
Blondon, M.; Perrier, A.; Nendaz, M.; Righini, M.; Boehlen, F.; Boulvain, M.; De Moerloose, P. Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery. Thromb. Haemost., 2010, 103(1), 129-137.
[77]
Nelson-Piercy, C.; MacCallum, P.; Mackillop, L. on behalf of the
Guidelines Committee of the Royal College of Obstetricians and
Gynaecologists. Reducing the risk of thrombosis and embolism
during pregnancy and the puerperium. RCOG 2009 Green-top
Guideline No. 37a. Royal College of Obstetricians and
Gynaecologists. London.
[78]
American College of Obstetricians and Gynecologists (ACOG).
Thromboembolism in pregnancy. Washington (DC), American
College of Obstetricians and Gynecologists (ACOG); Sep. 12, 2011.
[79]
Mazzolai, L.; Hohlfeld, P.; Spertini, F.; Hayoz, D.; Schapira, M.; Duchosal, M.A. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood, 2006, 108(5), 1569-1570.
[80]
Gerhardt, A.; Zotz, R.B.; Stockschlaeder, M.; Scharf, R.E. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. Thromb. Haemost., 2007, 97(3), 496-497.
[81]
Harenberg, J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb. Res., 2007, 119(3), 385-388.
[82]
Wijesiriwardana, A.; Lees, D.A.; Lush, C. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy. Blood Coagul. Fibrinolysis, 2006, 17(2), 147-149.
[83]
Knol, H.M.; Schultinge, L.; Erwich, J.J.; Meijer, K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J. Thromb. Haemost., 2010, 8(8), 1876-1879.
[84]
Elsaigh, E.; Thachil, J.; Nash, M.J.; Tower, C.; Hay, C.R.; Bullough, S.; Byrd, L. The use of fondaparinux in pregnancy. Br. J. Haematol., 2015, 168(5), 762-764.
[85]
Winger, E.E.; Reed, J.L. A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. Am. J. Reprod. Immunol., 2009, 62(4), 253-260.
[86]
Dempfle, C.E. Minor transplacental passage of fondaparinux in vivo. N. Engl. J. Med., 2004, 350(18), 1914-1915.
[87]
Bujold, E.; Roberge, S.; Lacasse, Y.; Bureau, M.; Audibert, F.; Marcoux, S.; Forest, J.C.; Giguere, Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet. Gynecol., 2010, 116(1), 402-414.
[88]
Askie, L.M.; Duley, L.; Henderson-Smart, D.J.; Stewart, L.A. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet, 2007, 369(9575), 1791-1798.
[89]
Duley, L.; Henderson-Smart, D.J.; Meher, S.; King, J.F. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev., 2007, (2)CD004659
[90]
Farquharson, R.G.; Quenby, S.; Greaves, M. Antiphospholipid syndrome in pregnancy: a randomized.; controlled trial of treatment. Obstet. Gynecol., 2002, 100(3), 408-413.
[91]
Baglin, T.; Barrowcliffe, T.W.; Cohen, A.; Greaves, M. for the British Committee for Standards in Haematology.Guidelines on the use and monitoring of heparin. Br. J. Haematol., 2006, 133(1), 19-34.
[92]
Okoroh, E.M.; Azonobi, I.C.; Grosse, S.D.; Grant, A.M.; Atrash, H.K.; James, A.H. Prevention of venous thromboembolism in pregnancy: a review of guidelines. 2000-2011. J. Womens Health (Larchmt.), 2012, 21(6), 611-615.
[93]
Patel, J.P.; Green, B.; Patel, R.K.; Marsh, M.S.; Davies, J.G.; Arya, R. Population pharmacokinetics of enoxaparin during the antenatal period. Circulation, 2013, 128(13), 1462-1469.
[94]
De Stefano, V.; Leone, G.; Mastrangelo, S.; Tripodi, A.; Rodeghiero, F.; Castaman, G.; Barbui, T.; Finazzi, G.; Bizzi, B.; Mannucci, P.M. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost., 1994, 71(6), 799-800.
[95]
Friederich, P.W.; Sanson, B.J.; Simioni, P.; Zanardi, S.; Huisman, M.V.; Kindt, I.; Prandoni, P.; Büller, H.R.; Girolami, A.; Prins, M.H. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann. Intern. Med., 1996, 125(12), 955-960.
[96]
Bonnar, J.; Norris, L.; Greene, R. Inherited thrombophilia: the obstetric prospective. Semin. Thromb. Hemost., 1998, 24(1), 49-53.
[97]
Lockwood, C.J. Inherited thrombophilias in pregnant patient: detection and treatment paradigm. Obstet. Gynecol., 2002, 99(2), 333-334.
[98]
Gohil, R.; Peck, G.; Sharma, P. The genetics of venous thromboembolism. A meta- analysis involving approximately 120,000 cases and 180,000 controls. Thromb. Haemost., 2009, 102(2), 360-370.
[99]
Ziakas, P.D.; Poulou, L.S.; Pavlou, M.; Zintzaras, E. Thrombophilia and venous thromboembolism in pregnancy: a meta-analysis of genetic risk. Eur. J. Obstet. Gynecol. Reprod. Biol., 2015, 191, 106-111.
[100]
Pabinger, I.; Grafenhofer, H.; Kyrle, P.A.; Quehenberger, P.; Mannhalter, C.; Lechner, K.; Kaider, A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood, 2002, 100(3), 1060-1062.
[101]
Brill-Edwards, P.; Ginsberg, J.S.; Gent, M.; Hirsh, J.; Burrows, R.; Kearon, C.; Geerts, W.; Kovacs, M.; Weitz, J.I. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N. Engl. J. Med., 2000, 343(20), 1439-1444.
[102]
Pabinger, I.; Grafenhofer, H.; Kaider, A.; Kyrle, P.A.; Quehenberger, P.; Mannhalter, C.; Lechner, K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J. Thromb. Haemost., 2005, 3(5), 949-954.
[103]
De Stefano, V.; Martinelli, I.; Rossi, E.; Battaglioli, T.; Za, T.; Mannucci, P.M.; Leone, G. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br. J. Haematol., 2006, 135(3), 386-391.
[104]
Rodger, M.A.; Betancourt, M.T.; Clark, P.; Lindqvist, P.G.; Dizon-Townson, D.; Said, J.; Seligsohn, U.; Carrier, M.; Salomon, O.; Greer, I.A. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med., 2010, 7(6)e1000292
[105]
Pasquier, E.; de Saint Martin, L.; Bohec, C.; Chauleur, C.; Bretelle, F.; Marhic, G.; Le Gal, G.; Debarge, V.; Lecomte, F.; Denoual-Ziad, C.; Lejeune-Saada, V.; Douvier, S.; Heisert, M.; Mottier, D. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood, 2015, 125(14), 2200-2205.
[106]
Rodger, M.A.; Hague, W.M.; Kingdom, J.; Kahn, S.R.; Karovitch, A.; Sermer, M.; Clement, A.M.; Coat, S.; Chan, W.S.; Said, J.; Rey, E.; Robinson, S.; Khurana, R.; Demers, C.; Kovacs, M.J.; Solymoss, S.; Hinshaw, K.; Dwyer, J.; Smith, G.; McDonald, S.; Newstead-Angel, J.; McLeod, A.; Khandelwal, M.; Silver, R.M.; Le Gal, G.; Greer, I.A.; Keely, E.; Rosene-Montella, K.; Walker, M.; Wells, P.S. TIPPS Investigators. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS), a multinational open-label randomised trial. Lancet, 2014, 384(9955), 1673-1683.
[107]
Kaandorp, S.P.; Goddijn, M.; van der Post, J.A.; Hutten, B.A.; Verhoeve, H.R.; Hamulyák, K.; Mol, B.W.; Folkeringa, N.; Nahuis, M.; Papatsonis, D.N.; Büller, H.R.; van der Veen, F.; Middeldorp, S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N. Engl. J. Med., 2010, 362(17), 1586-1596.
[108]
de Jong, P.G.; Kaandorp, S.; Di Nisio, M.; Goddijn, M.; Middeldorp, S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst. Rev., 2014, 7CD004734
[109]
Clark, P.; Walker, I.D.; Langhorne, P.; Crichton, L.; Thomson, A.; Greaves, M.; Whyte, S.; Greer, I.A. Scottish Pregnancy Intervention Study (SPIN) collaborators. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood, 2010, 115(21), 4162-4167.
[110]
Gris, J.C.; Mercier, E.; Quéré, I.; Lavigne-Lissalde, G.; Cochery-Nouvellon, E.; Hoffet, M.; Ripart-Neveu, S.; Tailland, M.L.; Dauzat, M.; Marès, P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood, 2004, 103(10), 3695-3699.
[111]
de Jong, P.G.; Quenby, S.; Bloemenkamp, K.W.; Braams-Lisman, B.A.; de Bruin, J.P.; Coomarasamy, A.; David, M.; DeSancho, M.T.; van der Heijden, O.W.; Hoek, A.; Hutten, B.A.; Jochmans, K.; Koks, C.A.; Kuchenbecker, W.K.; Mol, B.W.; Torrance, H.L.; Scheepers, H.C.; Stephenson, M.D.; Verhoeve, H.R.; Visser, J.; de Vries, J.I.; Goddijn, M.; Middeldorp, S. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. Trials, 2015, 16, 208.
[112]
Nissen, N.N.; Shankar, R.; Gamelli, R.L.; Singh, A.; DiPietro, L.A. Heparin and heparin sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem. J., 1999, 338(Pt 3), 637-642.
[113]
Elsayed, E.; Becker, R.C. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J. Thromb. Thrombolysis, 2003, 15(1), 11-18.
[114]
Bazzoni, G.; Beltrán Nuñez, A.B.; Mascellani, G.; Bianchini, P.; Dejana, E.; Del Maschio, A. Effect of heparin, dermatan sulfate, and related oligderivatives on human polymorphonuclear leukocyte functions. J. Lab. Clin. Med., 1993, 121(2), 268-275.
[115]
Silvestro, L.; Viano, I.; Marcario, M.; Colangelo, D.; Montrucchio, G.; Panico, S.; Fantozzi, R. Effects of heparin and its desulfated derivatives on leucocyte-endothelial adhesion. Semin. Thromb. Hemost., 1994, 20(3), 254-258.
[116]
Lever, R.; Hoult, J.R.; Page, C.P. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br. J. Pharmacol., 2000, 129(3), 533-540.
[117]
Nelson, R.M.; Cecconi, O.; Roberts, W.G.; Aruffo, A.; Lindhardt, R.J.; Bevilacqua, M.P. Heparin oligosaccharides bind L- and P- selectin and inhibit acute inflammation. Blood, 1993, 82(11), 3253-3258.
[118]
Young, E.; Venner, T.; Ribau, J.; Shaughnessy, S.; Hirsh, J.; Podor, T. Binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells. Thromb. Res., 1999, 96(5), 373-381.
[119]
Gao, Y. Li. N.; Fei. R.; Chen. Z.; Theng. S.; Zeng. X. P-selectin- mediated acute inflammation can be blocked by chemically modified, RO-heparin. Mol. Cells, 2005, 19(3), 350-355.
[120]
Peter, K.; Schwarz, M.; Conradt, C.; Nordt, T.; Moser, M.; Kubler, W.; Bode, C. Heparin inhibits ligand binding to leukocyte integrin Mac-1(CD11b/CD18). Circulation, 1999, 100(14), 1533-1539.
[121]
Wulczyn, F.G.; Krappmann, D.; Scheidereit, C. The NF-κB/Rel and I kappa B gene families: mediators of immune response and inflammation. J. Mol. Med., 1996, 74(12), 749-769.
[122]
Letourneur, D.; Caleb, B.L.; Castellot Jr, J.J. Heparin binding, internalization and metabolism in vascular smooth muscle cells: II. Degradation and secretion in sensitive and resistant cells. J. Cell. Physiol., 1995, 165(3), 687-695.
[123]
Thourani, V.H.; Brar, S.S.; Kennedy, T.P.; Thornton, L.R.; Watts, J.A.; Ronson, R.S.; Zhao, Z.Q.; Sturrock, A.L.; Hoidal, J.R.; Vinten-Johansen, J. Nonanticoagulant heparin inhibits NK-κB activation and attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2000, 278(6), H2084-H2093.
[124]
Manduteanu, I.; Voinea, M.; Antohe, F.; Dragomir, E.; Capraru, M.; Radulescu, L.; Simionescu, M. Effect of enoxaparin on high glucose- induced activation of endothelial cells. Eur. J. Pharmacol., 2003, 477(3), 269-276.
[125]
Hecht, I.; Hershkoviz, R.; Shivitel, S.; Lapidot, T.; Cohen, I.R.; Lider, O.; Cahalon, L. Heparin-dissacharide affects T cells: inhibition of NF kappaB activation, cell migration, and modulation of intracellular signaling. J. Leukoc. Biol., 2004, 75(6), 1139-1146.
[126]
Hochart, H.; Jenkins, P.V.; Smith, O.P.; White, B. Low molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br. J. Haematol., 2006, 133(1), 62-67.
[127]
Mousavi, S.; Moradi, M.; Khorshidahmad, T.; Motamedi, M. Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review. Adv. Pharmacol. Sci., 2015, 2015507151
